Merck, 662086-10MG, UCH-L1 Inhibitor

General description
A potent, reversible, competitive, and active site-directed inhibitor of ubiquitin C-terminal hydrolase L1 (UCH-L1) (Ki = 400 nM; IC₅₀ = 880 nM). Exhibits ~28-fold greater selectivity for UCH-L1 compared to UCH-L3 (Cat. No. 662090). Shown to increase proliferation of the UCH-L1-expressing tumor cell line, SH-SY5Y, at a concentration of 5 µM. Useful tool for studying the roles of UCH-L1 in cancer, Parkinson′s disease, and other neurological disorders. Cell-permeability is reported to vary from cell type to cell type.
An isatin O-acyl oxime compound that acts as a potent, reversible, competitive, and active site-directed inhibitor of UCH-L1 (Ki = 0.40 µM; IC₅₀ = 0.88 µM) with ~28-fold greater selectivity over UCH-L3 (Cat. No. 662090). Shown to increase proliferation of UCH-L1 expresssing tumor cell line SH-SY5Y at 5 µM. A useful tool for studying the roles of UCH-L1 in cancer, Parkinson’s disease, and other neurological disorders. Permeability may vary from cell type to cell type.
Biochem/physiol Actions
Cell permeable: no
Primary Target
UCH-L1
Product competes with ATP.
Reversible: yes
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Liu, Y., et al. 2003. Chem. Biol.10, 837.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Carcinogenic / Teratogenic (D)